We are thrilled to share that Ms. Jennifer Che, our President and Managing Director, has been recognized in IAM Strategy 300 Global Leaders 2026. This follows our recent announcement recognizing Ms. Che in the list of IAM Global Leaders 2026, which focuses on patent prosecution.

IAM Strategy 300 showcases the top strategy experts in the IP world. It is the “only resource of its kind, acknowledging leaders from across in-house, private practice and service provider roles”. A slot in the 300 is the “mark of a professional whose approach to intellectual property is regarded by peers as truly strategic in nature.”

IAM's comprehensive research process involved gathering nominations and insights from thousands of sources over a five month period, leading to in-depth interviews with selected candidates.

Jennifer's inclusion in this elite group is a testament to her ability to inspire and innovate, continually providing exceptional value to our clients and setting a benchmark in the industry.


Please join us in congratulating Jennifer on this well-deserved recognition. Her expertise and dedication to her work make her an invaluable asset to our team and our clients.

我們過去活動

Recommended Insights

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

2023年1月4日
Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO). Up until […]

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

2021年5月28日
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

2024年2月7日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]
Top crossarrow-right